IDH2 and glioblastoma: This is crucial for identifying the 10% of astrocytomas with noncanonical IDH mutations undetectedable using IDH R132H immunohistochemistry and for recognizing astrocytomas with molecular characteristics resembling glioblastoma (Whitfield and Huse, 2022).